Literature DB >> 28841705

Single nucleotide polymorphisms at miR-146a/196a2 and their primary ovarian insufficiency-related target gene regulation in granulosa cells.

Sung Hwan Cho1, Hui Jeong An1, Kyung Ah Kim1, Jung Jae Ko1, Ji Hyang Kim2, Young Ran Kim2, Eun Hee Ahn2, HyungChul Rah3, Woo Sik Lee4, Nam Keun Kim1.   

Abstract

MicroRNAs post-transcriptionally regulate gene expression in animals and plants. The aim of this study was to identify new target genes for microRNA polymorphisms (miR-146aC>G and miR-196a2T>C) in primary ovarian insufficiency (POI). We cloned and transfected miR-146aC>G and miR-196a2T>C into human granulosa cells and used microarrays and qPCR-arrays to examine the changes in the messenger RNA expression profile. We show miR-146aC>G and miR-196a2T>C change the mRNA expression patterns in granulosa cell. In each case, mRNAs were up or down-regulated after treatments with miR-146a C or G and miR-196a2 T or C. We found that miR-146a led to a significantly altered regulation of the mRNA levels of FOXO3, FOXL2 and CCND2 compared to controls. We also found that the polymorphisms of miR-146a led to a significantly altered regulation of CCND2 and FOXO3. Our results suggest that miR-146aC>G and miR-196a2T>C can regulate the levels of many of their target transcripts. In addition, specific target genes of miR-146aC>G polymorphisms may be involved in granulosa cell regulation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28841705      PMCID: PMC5571913          DOI: 10.1371/journal.pone.0183479

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Primary ovarian insufficiency (POI), also known as premature ovarian failure (POF), is the loss of ovarian function before age 40 [1]. A commonly cited triad for diagnosis is amenorrhea, hypergonadotropism, and hypoestrogenism. If it has a genetic cause, it may be called gonadal dysgenesis [2]. More than 90% of POI cases have unknown causes [3,4]. Recent studies indicate that microRNAs (miRNAs) are involved in ovarian pathologies, such as POI and polycystic ovarian syndrome (PCOS) [5,6]. miRNAs are small, noncoding, single-stranded RNA molecules bind a target messenger RNA (mRNA) [7]. Previous reports showed that miRNAs bind the 3’ untranslated region (UTR) of target mRNAs and modulate their gene expression through deregulation or translational repression [8]. A single miRNA may regulate multiple targets and thus acts as a master controller of gene expression [7,8]. Single nucleotide polymorphisms (SNPs) or mutations occurring in the miRNA gene region may affect the property of miRNAs by altering their expression and/or maturation [9]. miRNAs are also involved in the entire process of ovarian follicle development, including follicle growth and ovulation [10,11]. miR-146a is enriched in the oocyte. During bovine oocyte maturation and preimplantation embryo development, miR-146a undergoes changes in expression level [12]. The FAS gene, an inducer of oocyte apoptosis during folliculogenesis is an miR-146a target [13-15]. miR-196a2, which is expressed during oocyte maturation and early bovine embryonic development, regulates the expression of the newborn ovary homeobox (NOBOX) gene during bovine early embryogenesis [16]. NOBOX gene mutations have been reported to cause POI [12,17]. We previously reported the association between Recurrent Spontaneous Abortion (RSA) and POI with polymorphisms of miR-146a, miR-196a2 [12,18]. These results suggest that gene—gene interaction and transcriptional alterations between miR-146a and miR-196a2 may be involved in POI development [12, 19]. Therefore, we hypothesized that transcriptional alterations in miR-146aC>G and miR-196a2T>C might influence target gene expression and downstream oocyte apoptosis during folliculogenesis. To identify new target genes expressed in POI, we used a microarray gene expression analysis and validation for novel targets regulated by miR-146aC>G and miR-196a2T>C in granulosa cells. We identified putative candidates for the genes regulated by the miR-146aC>G polymorphism. Our data provide new insights into the potential targets of miR-146a in POI regulation.

Materials and methods

Ethics statement

The study protocol was approved by the Institutional Review Board of CHA Bundang Medical Center. All study subjects provided written informed consent to participate in the study. All methods used in this study were carried out in accordance with approved guidelines.

Study participants

All participants were Korean. They were recruited from the Department of Obstetrics and Gynecology of CHA Bundang Medical Center from March 1999 to February 2010. The study group consisted of 113 women (age range, 21–43 years; mean age ± standard deviation [SD], 31.34 ± 4.97 years) who were diagnosed with POI (cessation of menstruation before 40 years of age and two serum FSH levels >40 IU/L). Patients with a history of pelvic surgery, cancer, radiation exposure, autoimmune disorder, or genetic syndromes were excluded. The control group consisted of 227 women (age range, 23–43 years; mean age ± SD, 32.54 ± 3.88 years) who had regular menstrual cycles and at least one live birth. All participants provided informed consent.

Hormone analysis

To measure FSH, luteinizing hormone (LH), and estradiol (E2) levels, blood samples were collected on the second or third menstrual cycle day. The serum was separated as described previously [20], and hormone levels were measured using radioimmunoassay (E2; Beckman Coulter, Inc, Fullerton, CA, USA) or enzyme immunoassay (FSH and LH; Siemens, Los Angeles, CA, USA) according to the manufacturer’s instructions.

Genetic analysis of miRNA sequence polymorphisms

Genomic DNA was extracted from anticoagulated peripheral blood using a G-DEX blood extraction kit (iNtRON Biotechnology, Seongnam, South Korea). Nucleotide changes were determined using polymerase chain reaction—restriction fragment length polymorphism (PCR-RFLP) analysis as previously described [21]. Primer sequences for PCR amplification of each polymorphism were as follows: miR-146aC>G: forward 5’-CAT GGG TTG TGT CAG TGT CAG AGC T-3’ and reverse 5’-TGC CTT CTG TCT CCA GTC TTC CAA-3’ (mismatch sequence is underlined); miR-196a2T>C: forward 5’-CCC CTT CCC TTC TCC TCC AGA TA-3’ and reverse 5’-CGA AAA CCG ACT GAT GTA ACT CCG-3’. For miR-146aC>G and 196a2T>C polymorphisms, we digested PCR products with SacI and MspI respectively (New England BioLabs, Ipswich, MA, USA) at 37°C for 16 hours, We confirmed the genotype of the two sites by sequencing 10% of the samples.

miR-146a(C>G) and miR-196a2(T>C) expression vector construction

To amplify pre-miR-146aC or pre-miR-146aG from human genomic DNA previously determined to have the G or C genotype, we performed PCR using two primers 5’-GCC GAT GTG TTA TCC TCA GCT TTG-3’ and 5’-ACG ATG ACA GAG ATA TCC CAG-3’ were used to amplify pre-miR-146a-C or pre-miR-146a-G from each type of human genomic DNA by PCR. PCR products corresponding to pre-miR and its flanking regions (pre-miR-146aC, 322 bp; pre-miR-146aG, 322 bp; pre-miR-196a2T, 345 bp; and pre-miR-196a2C, 345bp) were amplified and cloned into the pcDNA3.1 expression vector (Invitrogen, Carlsbad, CA, USA). The sequences of the vectors were confirmed by direct sequencing; the only difference was in the SNP.

Cell transfection

Human granulosa cells (KGN) [22] were plated at 1×105 cells per well in a 6-well plate and transfected 24 h later using JetPRIME transfection reagent (Polyplus, Illkirch, France). Each transfection reaction contained 500 ng of miR-146aG (in pcDNA3.1) or 500 ng of miR-146aC (in pcDNA3.1). For controls, we performed mock transfection with scrambled plasmids (Cat No: 1027271, Qiagen, Valencia, CA, USA) transfection with empty pcDNA 3.1 plasmid (Invitrogen, Carlsbad, CA, USA) and used untransfected cells. Total RNA was extracted 24 h after transfection and used for real-time qRT-PCR.

RNA isolation and cDNA synthesis

Total RNA was isolated using TRIzol® Reagent (Catalog No. 15596–026) and a miRNeasy mini kit (Qiagen) with DNase treatment. cDNA was synthesized by using the miScript II RT Kit (Qiagen). Manufacturers’ protocols were used for all kits. Isolated miRNA was quantified using a Nanodrop ND 1000 (Thermo Fisher Scientific, Waltham, MA, USA), and 500 ng was used for the subsequent cDNA preparation protocol.

Microarray analysis

The hybridized Human Genome U133A 2.0 Array (Affymetrix, Santa Clara, CA, USA) was scanned and analyzed with the Affymetrix Microarray Analysis Suite version 5.0. The average density of hybridization signals from three independent samples was used for data analysis, and genes with signal density less than 300 pixels were omitted from the analysis. P-values were calculated with two-sided t-tests with unequal variance assumptions. To correct for multiple hypothesis testing, the false discovery rate was calculated. Differentially expressed genes were selected using both a false discovery rate of less than 0.01 and a fold change greater than 1.5 or less than 21.5. A tree cluster was generated by hierarchical cluster analysis to classify the miRNA-transfected cells. For this analysis, we used average linkage metrics and centered Pearson correlations (Cluster 3.0). Java Tree view 1.1 (http://sourceforge.net/projects/jtreeview/) was used for tree visualization.

qPCR array analysis

The ExProfile™ Gene qPCR Array 96-well-qPCR plate (CS-PAG-062515J1-96B6, GeneCopoeia Inc, Rockville, MD, USA) was used for this study. Each array has a panel of validated, optimized qPCR primers for 32 mRNAs associated with POI as well as the housekeeping genes GAPDH and ACTB, which are used as references to normalize expression. Each well contains a forward primer for the mRNA sequence cross-linked to the 96-well plate. The qPCR Primer Array was performed using 20 μl reaction volumes per well containing 1 μl reverse transcription product and detected using SYBR green, according to the manufacturer’s instructions. The arrays were performed on a Bio-Rad iCycler iQ™ instrument (Bio-Rad, Hercules, CA, USA).

Gene ontology analysis

To analyze the function of those genes, we used the DAVID software (https://david.ncifcrf.gov/)[23], which queries for biological activities according to Gene Ontology (GO) annotations.

Real-Time RT-PCR detection of miR-146a and miR-196a2

To evaluate miR-146a and miR-196a2 expression, real-time RT-PCR was used. RNA (500 ng) was used for RT-PCR reactions that were performed using an miScript II RT kit (Qiagen, Hilden, Germany) acording to the manufacturer’s protocol. When reverse transcription reactions are performed, mature miRNAs as well as certain small nucleolar RNAs and small nuclear RNAs are selectively converted into cDNA. Mature miRNAs are polyadenylated by poly(A) polymerase and reverse transcribed into cDNA using oligo-dT primers. The oligo-dT primers have a 3' degenerate anchor and a universal tag sequence on the 5' end, allowing amplification of mature miRNA at the real-time PCR step. Real-time PCR was performed on the Roter-Gene System. RNU6 RNA was used as an endogenous control. All primers were part of SYBR green assays for miR-146a, miR-196a2, or RNU6 (Qiagen, Hilden, Germany). The cycle number at which the product level exceeded an arbitrarily Ct (Cycle threshold) was determined for each target sequence, and the amount of each miRNA relative to RNU6 RNA was quantified using the formula 2-deltadeltaCt.

Validation of miR-146a target gene expression

Using the TargetRank software (http://genes.mit.edu/targetrank/), the alternative mature forms of miR-146a-3p and miR-196a2-3p were predicted to have several hundred target genes (using a Target Rankscore ≥0.35, 214 and 166 genes were found for miR-146a-3pC and miR-146a-3pG, respectively, (supplement information). Because each mature miRNA binds to a distinct set of target genes, different target genes are affected by the miRNAs produced by G or C homozygotes (miR-146a-3pC or miR-146a-3pG, respectively). We chose POI-related candidate target genes (FOXO3, FOXL2, DIAPH2, BDNF, CCND2, and FOXE1); however, there was no distinct set of POI-related target genes produced by miR-196a2-3p T or C homozygotes. To validate the regulation of miR-146a and miR-196a2 target gene expression, we used real-time qRT-PCR. Total RNA (500 ng) was used for RT reactions that were performed using the miScript II RT kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Real-time PCR was performed on the Roter-Gene system. For the quantitative analysis of predicted target genes, the primers were designed using Primer Premier 3 software (Table 1). GAPDH RNA was used as an endogenous control. All primers were part of SYBR green assays for miR-146a or miR-196a2 target genes or GAPDH (Bioneer, Daejeon, Korea). The cycle number at which the product level exceeded an arbitrarily Ct (Cycle threshold) was determined for each target sequence, and the amount of each target gene relative to GAPDH RNA was described using the formula2-deltadeltaCt.
Table 1

Sequence of primers used for validation of target genes with RT-qPCR.

miRNAtarget sequence of 3'UTR*PrimersAmplicon(bp)
miR-146aFOXO3F: TCAGTGAGCCAGACTTGCTT516
R: CCTTGTCCCTTCCTCAGCTGTTT
CCND2F: ATTGAACCATTTGGGATGGA325
R: AAGGGAACAAAATGCCACAC
DIAPH2F: AGGTGCAGCATTCAGAGA243
R: AAGTCATGTTGTACCATCACCC
BBS9F: TGCATAGAAAGAGGGGTTGG242
R: AACTGGCAAAGGCATATTTTT
FOXE1F: CCCCTTTCCCTTGAGAAATC309
R: CCCATTTGGACTGAACCAAG
FOXL2F: TCTTGGCCTTCTCTCACAGG230
R: TGCCGGGTTTCACATTTCTC
GapdhF: AGGTCGGAGTCAACGGATTT325
R: ATCTCGCTCCTGGAAGATGG

* miR-146a target prediction: Target Rank (http://genes.mit.edu/targetrank/)

* miR-146a target prediction: Target Rank (http://genes.mit.edu/targetrank/)

3’-UTR reporter gene assay

To generate 3’-UTR luciferase reporter constructs, 3’-UTRs from CCND2, FOXL2, FOXO3, and FOXE1 mRNAs were cloned downstream of the firefly luciferase gene in the pGL4.13-Control Vector (Promega, Madison, WI, USA). For luciferase reporter assays, KGN cells were plated at 1×105cells per well in 6-well dishes and co-transfected with jetPRIME reagent 24h later (Polyplus, Illkirch, France). Each co-transfection reaction contained 200 ng of pcDNA3::146aC or 200 ng of pcDNA3::146aG plus 200 ng of pGL4.13::3’-UTR of each target gene construct and 200 ng of pGL4.75 plasmid, which served as the normalization control (Promega, Madison, WI, USA). After 24 h, cells were washed and lysed with Passive Lysis Buffer (Promega, Madison, WI, USA), and firefly luciferase activity was measured using the Veritas Microplate Luminometer (Turner Biosystems, Foster City, CA, USA) and normalized to renilla luciferase activity. We ran all samples in triplicate and replicated the experiment three times.

Western blot analysis

Proteins were separated using 10.0% SDS polyacrylamide gel electrophoresis and transferred onto nitrocellulose membrane (Millipore, Bedford, MA, USA). The membrane was blocked with 5% non-fat dried milk in TBST (20 mM Tris-HCl, 150 mM NaCl, and 0.1% Tween 20, pH 7.5) for 1 h and incubated overnight at 4°C with each primary antibody. After washing with TBST buffer, membranes were incubated for 1 h at room temperature. Protein bands were visualized using an ECL chemiluminescence system (Amersham, Buckinghamshire, UK). Equal loading of samples was verified by Western blotting for GAPDH. Band intensities were quantified using Adobe Photoshop CS5 (Adobe Systems, San Jose, CA).

Statistical analysis

All experiments were conducted at least three times. Statistical significance between two groups was evaluated using a two-tailed Student's t test. This statistical analysis was performed with GraphPad Prism software 4.0 (GraphPad Software Inc, San Diego, CA, USA). Differences were considered statistically significant at P < 0.05. Associations between gene modulations due to the two miRNAs were examined using a two-sided Fisher exact test. Associations between modulations by any two miRNAs was statistically significant if P < 0.001. Correlations between each genotype or allele and FSH, LH or E2 levels were assessed using Kruskal-Wallis and Mann-Whitney tests and P < 0.05 was considered statistically significant. These statistical analysis were performed using, MedCalc version 12.1.4 (MedCalc Software).

Results

Expression of miR-146aC>G and miR-196a2T>C in granulosa cells

Pre-miR-146a, mature-miR-146a, and mature-miR-146a-3p were expressed from C and G alleles; however, the amount of expression differed between the alleles (Fig 1). The mean expression of pre-miR-146a in G was 46% lower than in C (P = 0.005), expression of mature-miR-146a with G was 47% lower than with C (P = 0.0004), and mature-miR-146a-3p with G was 12% lower than with C (P = 0.005) (Fig 1C). The mean pre-miR-196a2 expression with CC was not lower than with TT (P = 0.005) (Fig 1D).
Fig 1

Expression of miR-146aC>G and miR-196a2T>C.

(A) Levels of mature miR-146a and (B) Levels of mature miR-196a2 in cells transfected with pri-miR-146a-GG, pri-miR-146a-CC or pri-miR-196a2TT, pri-miR-196a2CC by reverse transcription quantitative polymerase chain reaction. (C) Real-time quantitative PCR was used to detect the expression levels of pre, mature, and mature-3p in miR-146aC>G (rs2910164) and (D) miR-196a2T>C (rs11614913). Data are reported as means (±SD) from three independent experiments. Data are normalized to the reference RNU6. P<0.05 was considered statistically significant. PR: Pre-form, Mature: mature form, -3p: mature form of passenger strand.

Expression of miR-146aC>G and miR-196a2T>C.

(A) Levels of mature miR-146a and (B) Levels of mature miR-196a2 in cells transfected with pri-miR-146a-GG, pri-miR-146a-CC or pri-miR-196a2TT, pri-miR-196a2CC by reverse transcription quantitative polymerase chain reaction. (C) Real-time quantitative PCR was used to detect the expression levels of pre, mature, and mature-3p in miR-146aC>G (rs2910164) and (D) miR-196a2T>C (rs11614913). Data are reported as means (±SD) from three independent experiments. Data are normalized to the reference RNU6. P<0.05 was considered statistically significant. PR: Pre-form, Mature: mature form, -3p: mature form of passenger strand.

Gene ontology analysis from the microarray data

To investigate the regulation of POI-related target genes of miR-146aC>G and miR-196a2T>C, we used microarray data. To analyze the function of those genes, we used DAVID software, which queries for biological activities according to GO annotations. The DAVID functional analysis of miR-146aC>G (Fig 2A) showed that the main biological processes altered between the wild-type C allele and the variant types were cell differentiation (22 and 4 genes, respectively), metabolism (30 and 17 genes, respectively), cell growth (22 and 4 genes, respectively), and regulation of genes often involved in reproductive diseases 28 and 11 genes, respectively). The cellular components altered between wild-type and variant-type miR-146aC>G were intracellular (79 and 34genes, respectively) and extracellular (21 and 3 genes, respectively) (Fig 2B). The main molecular functions of miR-146aC>G altered between wild type and variant type were nucleic acid binding (61 and 24 genes, respectively), calcium ion binding (12 and 2 genes, respectively), and protein binding (9 and 3genes, respectively) (Fig 2C). The DAVID functional analysis for miR-196a2T>C (Fig 2A) showed that the main biological processes altered between the wild-type T allele and variant type were regulation of gene expression (23 and 55 genes, respectively), metabolism (35 and 70 genes, respectively), and cell organization and biogenesis (16 and 31 genes, respectively). The main cellular components altered between wild-type and variant-type miR-146aC>G were intracellular (76 and 145genes, respectively) and extracellular (12 and 18genes, respectively) (Fig 2B). The main molecular function of miR-146aC>G altered between wild type and variant type were nucleic acid binding (62 and 125genes, respectively), calcium ion binding (8 and 13genes, respectively), transferase (19 and 30genes, respectively), and transcription factors (13 and 34genes, respectively)(Fig 2C).
Fig 2

Gene Ontology for 2×up and down-regulated genes by miR-146a and miR-196a2.

The expression of miR-146a and miR-196a2 in granulosa cells was assessed by microarray. (A) Target gene frequency for miR-146a [Wild type (C): black, variant (G): silver] and miR-196a2 [Wild type (T): black, variant (C): silver] in biological process, (B) cellular components, and (C) molecular function.

Gene Ontology for 2×up and down-regulated genes by miR-146a and miR-196a2.

The expression of miR-146a and miR-196a2 in granulosa cells was assessed by microarray. (A) Target gene frequency for miR-146a [Wild type (C): black, variant (G): silver] and miR-196a2 [Wild type (T): black, variant (C): silver] in biological process, (B) cellular components, and (C) molecular function.

Validation of microarray data and POI-related miR-146a target gene identification

To examine the reliability of the array data, we randomly selected eight mRNAs detected by microarray (S1 Fig) to confirm their expression in a granulosa cell line using qPCR. The results from the qRT-PCRs were consistent with the microarray data (S1 Fig). Using the TargetRank software (http://genes.mit.edu/targetrank/), we found that the alternative mature forms of miR-146a-3p and miR-196a2-3p were predicted to have several hundred target genes (data not shown). Using a Target Rank score of ≥0.35, 214 and 166 genes were found for miR-146a-3pC and for miR-146a-3pG, respectively (S1 Table). Because each mature miRNA bound to a distinct set of target genes, different target genes were affected by the miRNAs produced by G or C homozygotes (miR-146a and miR-146a-3pC or miR-146a-3pG, respectively). We chose POI-related target genes from micro array data (FOXO3, FOXL2, DIAPH2, BDNF, CCND2, and FOXE1) (Table 1, S2 Table). No distinct set of POI-related target genes produced by miR-196a2-3p T or C homozygotes were found. To examine the reliability of the POI-related target gene expression, we selected six mRNAs detected by microarray (Fig 3A–3F). Six individual target mRNAs were further examined in an independent set of RNA samples using the qPCR-array and Real time PCR. As shown in Fig 3, individual expression using the micro array confirmed the result of the Real time PCR (Fig 3A–3F) and qPCR-array (Fig 3G–3L) analysis for all six genes.
Fig 3

Expression of POI-related miR-146aC>G target genes.

Validation of the expression of down-regulated genes from microarrays (A-F) and qPCR-arrays (G-L). Transient transfection of pGL4.13 plasmids with FOXO3, FOXl2, ESR1, BBS9, DIAPH2, and FOXE1 in the KGN cell line. mRNA expression levels were normalized to those of GAPDH expression. The data indicate the mean values with the standard deviation relative to miR-mimic negative expression from three independent experiments. Control (miR-scrambled + pGL4.13–3’UTR of each target gene). *P<0.05 was considered statistically significant.

Expression of POI-related miR-146aC>G target genes.

Validation of the expression of down-regulated genes from microarrays (A-F) and qPCR-arrays (G-L). Transient transfection of pGL4.13 plasmids with FOXO3, FOXl2, ESR1, BBS9, DIAPH2, and FOXE1 in the KGN cell line. mRNA expression levels were normalized to those of GAPDH expression. The data indicate the mean values with the standard deviation relative to miR-mimic negative expression from three independent experiments. Control (miR-scrambled + pGL4.13–3’UTR of each target gene). *P<0.05 was considered statistically significant.

Regulation of 3’-UTR of target genes from the miR-146a polymorphisms

To analyze the effect of miR-146aC>G on mRNA levels of six putative target genes (FOXO3, FOXL2, DIAPH2, BDNF, CCND2, and FOXE1) identified from microarray and qPCR-array data, we constructed an expression vector system and quantified the abundance of candidate mRNAs reported to be regulated by miR-146a using real-time PCR (Applied Biosystems, Foster City, CA, USA)(Fig 4). We observed a significant reduction in mRNA expression in the cells co-transfected with both pcDNA3.1-miR-146aC and pGL-4.13–3’UTR(FOXO3), pGL4.13–3’UTR(CCND2), or pGL4.13–3’UTR(FOXL2) compared to the cells co-transfected with both pcDNA3.1-miR-146aG and pGL4.13–3’UTR(FOXO3), pGL4.13–3’UTR(CCND2), or pGL4.13–3’UTR(FOXL2), indicating miR-146aC>G could regulate the 3’UTRs of FOXO3, CCND2, and FOXL2 mRNAs in the Human granulosa cell line (Fig 4).
Fig 4

Validation of POI-related miR-146aC>G target genes.

Validation of the expression using qRT-PCR. Transient transfection of pGL4.13 plasmids with FOXO3, FOXl2, ESR1, BBS9, DIAPH2, and FOXE1 in the KGN cell line. mRNA expression levels were normalized to those of GAPDH expression. The data indicate the mean values with the standard deviation relative to miR-mimic negative expression from three independent experiments. Control (miR-scrambled + pGL4.13–3’UTR of target gene). *P<0.05 was considered statistically significant.

Validation of POI-related miR-146aC>G target genes.

Validation of the expression using qRT-PCR. Transient transfection of pGL4.13 plasmids with FOXO3, FOXl2, ESR1, BBS9, DIAPH2, and FOXE1 in the KGN cell line. mRNA expression levels were normalized to those of GAPDH expression. The data indicate the mean values with the standard deviation relative to miR-mimic negative expression from three independent experiments. Control (miR-scrambled + pGL4.13–3’UTR of target gene). *P<0.05 was considered statistically significant. To experimentally confirm the interaction between miR-146aC>G and FOXO3 and CCND2, we applied reporter gene assays. We cloned fragments of 3’UTR segments of FOXO3 or CCND2 into the pGL4.13 expression reporter vector (Promega, Madison, WI, USA). Then, we transfected pGL-4.13–3’-UTR (FOXO3) and pGL-4.13–3’UTR (CCND2) into KGN cell lines with or without pcDNA3.1-miR-146a. Either C or G alleles of miR-146a were used in the analyses. After 24 hours, we observed a significant reduction of luciferase activity in the cells transfected with both pcDNA3.1-miR-146a and pGL-4.13–3’UTR(FOXO3) or pGL-4.13–3’UTR(CCND2) compared to the cells transfected with pGL-4.13–3’UTR(FOXO3) or pGL-4.13–3’UTR(CCND2) alone or with scrambled miRNA (Fig 5C and 5D), indicating miR-146aC>G could bind to the 3’UTRs of FOXO3 and CCND2 mRNAs in vitro.
Fig 5

Effects of miR-146aC>G on the luciferase reporter gene with the 3’-UTR of FOXO3 and CCND2.

Schematic representation of target genes 3´-UTRs that have presumed miR-146a-3p-C and miR-146a-3p-G binding sites in conserved regions (A and B). Transient transfection of pGL4.13 plasmids with FOXO3 (C) and CCND2 (D) into the KGN cell line with miR-146aC>G in pcDNA3.1. Luciferase expression levels were normalized using renilla luciferase expression. Western blot was used to detect FOXO3 and CCND2 protein levels in each group (E and F). KGN cells were transfected with miR-146aC or miR-146aG in pcDNA3.1 or controls. Protein expression levels were normalized using GAPDH expression. The expression data are the mean ± standard deviation of three independent experiments normalized to the miR-mimic (off-target) negative control. Control: miR-scrambled + target construct + pGL4.75, 146aC: miR-146aC + target construct + pGL4.75, 146aG: miR-146aG + target construct + pGL4.75. P<0.05 was considered statistically significant.

Effects of miR-146aC>G on the luciferase reporter gene with the 3’-UTR of FOXO3 and CCND2.

Schematic representation of target genes 3´-UTRs that have presumed miR-146a-3p-C and miR-146a-3p-G binding sites in conserved regions (A and B). Transient transfection of pGL4.13 plasmids with FOXO3 (C) and CCND2 (D) into the KGN cell line with miR-146aC>G in pcDNA3.1. Luciferase expression levels were normalized using renilla luciferase expression. Western blot was used to detect FOXO3 and CCND2 protein levels in each group (E and F). KGN cells were transfected with miR-146aC or miR-146aG in pcDNA3.1 or controls. Protein expression levels were normalized using GAPDH expression. The expression data are the mean ± standard deviation of three independent experiments normalized to the miR-mimic (off-target) negative control. Control: miR-scrambled + target construct + pGL4.75, 146aC: miR-146aC + target construct + pGL4.75, 146aG: miR-146aG + target construct + pGL4.75. P<0.05 was considered statistically significant.

Endogenous regulation of target proteins from the miR-146a polymorphisms

Endogenous FOXO3, CCND2, FOXE1 and FOXL2 expression levels were detected by performing Western blots of KGN cells transfected with miR-146aC, miR-146aG or control (pcDNA3.1 and a miRNA-mimic off-target control) (Fig 5E and 5F and S2 Fig). FOXO3 protein level was significantly diminished when cells were transfected with miR-146aC compared with miR-146aG or off-target control, By contrast, CCND2 protein level showed no marked difference when cells were transfected with miR-146aC compared with miR-146aG or off-target control (Fig 5E and 5F).

Clinical characteristics

FSH, LH, and E2 levels of POI patients and controls are summarized in Table 2. Patients with POI had significantly increased FSH and LH levels (p<0.0001, p<0.0001) and Patients with POI had decreased E2 levels compared with control women (p<0.0001). However, hormonal levels were not significantly different between POI patients and control subjects with miR-146aC>G and miR-196a2T>C (Table 3).
Table 2

Clinical variables of Korean participants in the primary ovarian insufficiency (POI) patients and control groups.

CharacteristicsControlsPOI patientsP value
Age mean ± SD (range)33.34 ± 5.70 (23–43)31.34 ± 4.97 (21–43)NS
FSH (mIU/ml) mean ± SD8.12 ± 2.8566.46 ± 14.11<0.0001
LH (mIU/ml) mean ± SD3.32 ± 1.76126.23 ± 10.68<0.0001
Estradiol (pg/ml) mean ± SD26 ± 14.757.93 ± 2.59<0.0001

Abbreviations: SD, standard deviation; NS, not significant; FSH, follicle-stimulating hormone; LH, luteinizing hormone; P value by t test.

Table 3

FSH, LH and E2 levels of control and POI participants based on miRNA polymorphic genotype.

FSH(mIU/mL) mean ± SDLH(mIU/mL) mean ± SDE2(pg/mL) mean ± SD
Genotypescontrolpatientscontrolpatientscontrolpatients
miR-146aC>G
CC8.46 ± 3.5361.29 ± 13.523.3 ± 1.7526.01 ± 7.1925.75 ± 12.347.91 ± 2.97
CG8.05 ± 2.4462.05 ± 14.443.44 ± 1.8426.70 ± 13.9826.95 ± 16.087.62 ± 1.73
GG7.45 ± 2.3965.44 ± 14.782.88 ± 1.2325.26 ± 3.7822.6 ± 15.348.93 ± 3.63
P0.5110.5330.5670.8560.610.144
miR-196a2T>C
TT7.8 ± 2.1762.09 ± 13.382.67 ± 1.2228.80 ± 17.7123.52 ± 10.638.50 ± 3.40
TC8.57 ± 3.1663.58 ± 15.633.40 ± 1.9925.85 ± 9.0527.60 ± 15.617.74 ± 2.24
CC7.23 ± 2.2060.30 ± 12.013.51 ± 1.2625.12 ± 5.7723.70 ± 14.707.82 ± 2.51
P0.1010.5010.2390.3430.3830.412

Abbreviations: SD, standard deviation; FSH, follicle-stimulating hormone; LH, luteinizing hormone; POI, Primary ovarian insufficiency; P value by ANOVA test.

Abbreviations: SD, standard deviation; NS, not significant; FSH, follicle-stimulating hormone; LH, luteinizing hormone; P value by t test. Abbreviations: SD, standard deviation; FSH, follicle-stimulating hormone; LH, luteinizing hormone; POI, Primary ovarian insufficiency; P value by ANOVA test.

Discussion

Increasing evidence supports the role of microRNAs in reproductive disorders [24-27]. In this context, evidence supporting the role of miR-146a and miR-196a2 in oocyte maturation and preimplantation embryo development [13, 28] has also been accumulating, which led us to investigate whether these miRNA SNPs (miR-146aC>G and miR-196a2T>C) influence the risk of POI-related genes in Korean woman. We previously showed that the combined genotypes and haplotypes of miR-146aC>G, miR-196a2T>C could be associated with POI in Korean women [12]. We also found that the expression of pre, mature, and mature-3p miR-146a with the G allele was significantly lower (P<0.05) than that of miR-146a with the C allele (Fig 1C), [19]. These results suggest that the polymorphisms in miR-146a could change their target gene expression [19]. The recent identification of miRNAs as an important posttranscriptional gene regulator elucidated the role of posttranscriptional gene regulation in reproductive disease [24,25]. In addition, miRNAs are involved in crucial cell processes, such as apoptosis, differentiation, and oncogenesis by regulating signal transduction pathways [29]. To investigate regulation of the POI-related target genes of miR-146aC>G and miR-196a2T>C, we used microarray data and prediction tools. To analyze the function of those genes from the microarray data, we used DAVID software [30], which provides a comprehensive set of functional annotation tools for investigators to understand biological meaning behind large list of genes according to GO annotations [30]. The functional analysis of miR-146aC>G and miR-196a2T>C showed that the main biological processes altered between wild type and variant type were cell differentiation, metabolism, cell growth, and regulation of genes often involved in reproductive diseases (Fig 2). Using TargetRank (http://genes.mit.edu/targetrank/), we found that the alternative mature forms of miR-146a-3p and miR-196a2-3p were predicted to have several hundred target genes (using a Target Rank score of ≥0.35, 214 and 166 genes were found for miR-146a-3pC and miR-146a-3pG, respectively, and 55 genes were found for miR-196a2-3p T or C; data not shown). Of those genes, we selected the POI-related miR-146aC>G target genes FOXO3, FOXL2, DIAPH2, BDNF, CCND2, and FOXE1. Previously, our work suggested that the gene—gene interaction between miR-146a and miR-196a2could be involved in POI development [12]; however, we did not observe any expression changes associated with miR-196a2 polymorphisms (Fig 1C), [19]. To further determine the function of the differentially expressed target genes of miR-146a-C>G, we investigated transcriptional regulation of FOXO3, FOXL2, DIAPH2, BBS9, CCND2, and FOXE1 as target genes of miR-146aC>G polymorphisms. We found that miR-146a leads to a significant regulation of the mRNA levels of FOXO3, FOXL2, and CCND2 compared to controls (Fig 4). Of note, FOXO3 is targeted by miR-146a-3pC. Because Foxo3 functions as a master regulator and potent suppressor of primordial follicle activation, loss of function in the mouse leads to POI due to global follicle activation [31]. The FOXO3 gene encodes the forkhead family of transcription factors, which is characterized by a distinct forkhead domain [32]. FOXO3 likely functions as an apoptosis trigger by activating genes necessary for cell death [33]. Numerous studies report that FOXO3-deficient ovaries exhibit defects in oocyte apoptosis [34-36]. In addition, mutations in FOXO1 and FOXO3 have been identified in women with POI [37]. We also found that CCND2 is regulated by miR-146aC>G. CCND2 involved in Wnt signaling, cell-cycle pathways, and adhesion molecule formation [38]. In addition, Wnt signaling and cell-cycle pathways are crucial in POI patients [39]. CCND2 plays an important role in initiating the early-to-mid G1 phase transition and is required for granulosa cell proliferation during ovarian folliculogenesis [40]. These results raise the possibility that miRNA polymorphisms may contribute to dysregulation and/or functional variations of the CCND2, FOXO3. Because FOXL2 is suggested to play a role in ovarian development and function [41], it may be an important mediator of ovarian development through miR-146a. However, it remains unknown whether FOXL2 is a target of miR-146a activity. To experimentally confirm the interaction between miR-146aC>G and FOXO3 or CCND2, we used reporter gene and Western blot assays. We observed a marked luciferase level reduction in cells co-expressing miR-146aC and the 3’-UTR of FOXO3-luc. or the 3’-UTR of CCND2-luc. However, luciferase levels were not reduced as efficiently in cells co-expressing miR-146aG and the 3’-UTR of FOXO3-luc. or the 3’-UTR of CCND2-luc. (Fig 5C and 5D). These findings suggest that miR-146a polymorphisms differentially affect CCND2 and FOXO3 expression. We observed that miR-146a directly binds the 3’UTR of the target gene potentially regulating the expression of target gene mRNA. More interestingly, we observed that the binding capacity of miR-146a to the 3’-UTR of target genes was significantly stronger in cell lines transfected with the wild-type C allele compared with those transfected with the G allele. This observation indicates that the binding capacity was significantly different between common and variant alleles (C and G type). We also confirmed that FOXO3 was decreased by western blot (Fig 5E). These results are consistent with our observation that the wild-type C allele had higher levels of mature miR-146a than the mutant G allele. A recent study showed that miR-146a, miR-27a, miR-23a, and miR-126 were highly expressed in plasma from POI patients compared with controls; fold change was 5.19, 2.98, 2.75, and 2.29 respectively [42]. Furthermore, in isolated ovarian granulosa cells from patients with POI, the expression of miR-146a was markedly increased [43]. These results suggest that miR-146a is significantly upregulated in POI patients compared with normal controls. In addition, numerous studies have implicated miR-146a in cell apoptosis [44-46]. miR-146a has been reported to contribute to granulosa cell apoptosis [47]. These results indicate that miR-146a plays an important role in the apoptosis of ovarian granulosa cells in patients with POI. Our previous association data also indicated that the miR-146aC allele in combination with the miR-196a2T allele increased POI risk. By contrast, the miR-146aG allele in combination with the miR-196a2T allele reduced POI risk. (OR: 0.193, 95% CI: 0.037–1.002, P<0.05) [12]. Thus, the C-allele type of miR-146a interacts more effectively with target genes (FOXO3 and CCND2) than the G-allele type, increasing the negative effects of POI. A previous report showed that targeted disruption of FOXO3 in granulosa cells leads to the production of ovarian-derived factor(s) that potently suppresses pituitary FSH biosynthesis [48]. Therefore, we examined if polymorphisms of miR-146aC>G influence FSH, LH and E2 levels via regulation of FOXO3. We used ANOVA to determine if there are any statistically significant differences between hormonal levels (FSH, LH, E2) and miR-146aC>G. While no significant difference was found, there was a trend of increasing FSH levels with the miR-146aG polymorphic variant. Taken together, our data suggest a model where miR-146a might play a role in the regulation of FOXO3 and CCND2, and a functional genetic variant in miR-146a can alter the expression of mature miR-146 and thereby affect POI-related target gene expression. Therefore, it is biologically plausible that the miR-146aC>G genetic variant may influence POI susceptibility by altering the expression of miR-146a target genes (e.g., FOXO3, FOXL2 and CCND2). In this work, the miRNA target sites of interest in the 3’-UTR of (FOXO3 and CCND2) were cloned downstream of a reporter gene (luciferase). Transfection of wild-type and variants of miR-146a resulted in altered expression of luciferase and FOXO3 proteins, indicating that polymorphisms of miR-146aC>G could be responsible for the differential translation in this in vitro system. However, the 3′-UTRs may contain multiple targeting sequences and other regulatory elements. Further assays to test each miRNA targeting sequence are needed. One limitation of our study is that we could not compare expression levels of miRNAs and target genes in ovary samples collected from patients with POI who had been miRNA genotyped because we had limited access to these samples. While we have not identified the underlying mechanisms by which miR-146aC>G polymorphisms affect the development of POI, the data suggest that miR-146aC>G polymorphisms could contribute to regulation of POI-related target genes, specifically FOXO3. Further studies of other pre-miRNA polymorphisms in diverse ethnic populations will advance our understanding of the role of miRNA polymorphisms in POI and POI target gene regulation.

Conclusion

Several genetic studies using the candidate gene approach have now been undertaken, and many potentially causal gene variants have been identified in POI [4, 49,50]. However, there are no examples that show how the SNP polymorphisms at the miRNA level affect the 3’-UTR of miRNA target genes in POI. We found evidence that the genetic polymorphism in miR-146aC>G regulated several POI-related target genes. Previous reports showed that polymorphisms in the miR-146a precursor (rs2910164) altered the expression of pre- and mature miR-146a [51-53]. To the best of our knowledge, this is the first report to evaluate POI-related gene regulation by miR-146a polymorphisms. As more experimental information about transcriptional regulation of miRNA genes themselves and their target genes is reported, we could extend the current study to have a deeper understanding of miRNA target gene regulation and the relationship between the regulation of miRNA genes and that of their targets in POI.

Validation of microarray data by real-time PCR.

mRNA was extracted following miR-146aC and miR-146aG expression. The expression of mRNAs relative to GAPDH RNA was determined by real-time PCR. (TIF) Click here for additional data file.

Western blot was used to detect FOXE1 and FOXL2 protein levels in each group.

KGN cells were transfected with miR-146aC or miR-146aG in pcDNA3.1 or controls. Protein expression levels were normalized using GAPDH expression. (TIF) Click here for additional data file.

Target genes of miR-146aC>G predicted using TargetRank software.

(DOCX) Click here for additional data file.

Putative miR-146a binding target genes.

(DOCX) Click here for additional data file.
  51 in total

1.  Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a.

Authors:  Diego H Castrillon; Lili Miao; Ramya Kollipara; James W Horner; Ronald A DePinho
Journal:  Science       Date:  2003-07-11       Impact factor: 47.728

2.  Specificity of the requirement for Foxo3 in primordial follicle activation.

Authors:  George B John; Lane J Shirley; Teresa D Gallardo; Diego H Castrillon
Journal:  Reproduction       Date:  2007-05       Impact factor: 3.906

3.  The expression profile of micro-RNA in endometrium and endometriosis and the influence of ovarian steroids on their expression.

Authors:  Qun Pan; Xiaoping Luo; Tannaz Toloubeydokhti; Nasser Chegini
Journal:  Mol Hum Reprod       Date:  2007-08-31       Impact factor: 4.025

4.  Expression pattern of endothelin system components and localization of smooth muscle cells in the human pre-ovulatory follicle.

Authors:  Dong-Hee Choi; Eun Kyung Kim; Kyeoung-Hwa Kim; Kyung-Ah Lee; Dong-Wook Kang; Hey Young Kim; Phillip Bridges; Chemyong Ko
Journal:  Hum Reprod       Date:  2011-03-15       Impact factor: 6.918

5.  Emerging functions of microRNA-146a/b in development and breast cancer: microRNA-146a/b in development and breast cancer.

Authors:  Hanan S Elsarraj; Shane R Stecklein; Kelli Valdez; Fariba Behbod
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-02-19       Impact factor: 2.673

Review 6.  Potential regulatory functions of microRNAs in the ovary.

Authors:  Tannaz Toloubeydokhti; Orhan Bukulmez; Nasser Chegini
Journal:  Semin Reprod Med       Date:  2008-10-24       Impact factor: 1.303

7.  Sequence variation at the human FOXO3 locus: a study of premature ovarian failure and primary amenorrhea.

Authors:  Teresa D Gallardo; George B John; Karen Bradshaw; Corrine Welt; Renee Reijo-Pera; Peter H Vogt; Philippe Touraine; Silvia Bione; Daniela Toniolo; Lawrence M Nelson; Andrew R Zinn; Diego H Castrillon
Journal:  Hum Reprod       Date:  2007-10-23       Impact factor: 6.918

8.  MicroRNA-196a regulates bovine newborn ovary homeobox gene (NOBOX) expression during early embryogenesis.

Authors:  Swamy K Tripurani; Kyung-Bon Lee; Gabbine Wee; George W Smith; Jianbo Yao
Journal:  BMC Dev Biol       Date:  2011-05-06       Impact factor: 1.978

9.  A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus.

Authors:  Xiaobing Luo; Wanling Yang; Dong-Qing Ye; Huijuan Cui; Yan Zhang; Nattiya Hirankarn; Xiaoxia Qian; Yuanjia Tang; Yu Lung Lau; Niek de Vries; Paul Peter Tak; Betty P Tsao; Nan Shen
Journal:  PLoS Genet       Date:  2011-06-30       Impact factor: 5.917

Review 10.  Single-nucleotide polymorphisms among microRNA: big effects on cancer.

Authors:  Feng-Ju Song; Ke-Xin Chen
Journal:  Chin J Cancer       Date:  2011-06
View more
  7 in total

1.  Association between miR-146a C > G, miR-149 T > C, miR-196a2 T > C, and miR-499 A > G polymorphisms and susceptibility to idiopathic recurrent pregnancy loss.

Authors:  Meysam Alipour; Maryam Abtin; Asghar Hosseinzadeh; Masoud Maleki
Journal:  J Assist Reprod Genet       Date:  2019-10-11       Impact factor: 3.412

2.  Deducting MicroRNA-Mediated Changes Common in Bronchial Epithelial Cells of Asthma and Chronic Obstructive Pulmonary Disease-A Next-Generation Sequencing-Guided Bioinformatic Approach.

Authors:  Ming-Ju Tsai; Yu-Chen Tsai; Wei-An Chang; Yi-Shiuan Lin; Pei-Hsun Tsai; Chau-Chyun Sheu; Po-Lin Kuo; Ya-Ling Hsu
Journal:  Int J Mol Sci       Date:  2019-01-28       Impact factor: 5.923

3.  Lnc-GULP1-2:1 affects granulosa cell proliferation by regulating COL3A1 expression and localization.

Authors:  Guidong Yao; Yue Kong; Guang Yang; Deqi Kong; Yijiang Xu; Jiahuan He; Ziwen Xu; Yucheng Bai; Huiying Fan; Qina He; Yingpu Sun
Journal:  J Ovarian Res       Date:  2021-01-20       Impact factor: 4.234

4.  Association of miR-146a and miR196a2 genotype with susceptibility to idiopathic recurrent pregnancy loss in Iranian women: A case-control study.

Authors:  Emad Babakhanzadeh; Hamid Danaei; Mohammad Abedinzadeh; Hamid Reza Ashrafzadeh; Nasrin Ghasemi
Journal:  Int J Reprod Biomed       Date:  2021-09-09

5.  Circular RNA expression profiles and CircSnd1-miR-135b/c-foxl2 axis analysis in gonadal differentiation of protogynous hermaphroditic ricefield eel Monopterus albus.

Authors:  Zhi He; Zhijun Ma; Deying Yang; Qiqi Chen; Zhide He; Jiaxiang Hu; Faqiang Deng; Qian Zhang; Jiayang He; Lijuan Ye; Hongjun Chen; Liang He; Xiaoli Huang; Wei Luo; Shiyong Yang; Xiaobin Gu; Mingwang Zhang; Taiming Yan
Journal:  BMC Genomics       Date:  2022-08-03       Impact factor: 4.547

Review 6.  Premature Ovarian Insufficiency: Past, Present, and Future.

Authors:  Seung Joo Chon; Zobia Umair; Mee-Sup Yoon
Journal:  Front Cell Dev Biol       Date:  2021-05-10

Review 7.  Panomics for Precision Medicine.

Authors:  Charanjit Sandhu; Alia Qureshi; Andrew Emili
Journal:  Trends Mol Med       Date:  2017-12-05       Impact factor: 15.272

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.